NCT01301430View on ClinicalTrials.gov

Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Glioblastoma Multiforme
Interventions
DRUG

H-1PV

H-1PV administered at three increasing doses either intratumorally or intravenously and then 10 days after the first administration intracerebrally (into the walls of tumor resection cavity).

Trial Locations (1)

69120

Department of Neurosurgery, University Hospital Heidelberg, Heidelberg

All Listed Sponsors
lead

Oryx GmbH & Co. KG

INDUSTRY

NCT01301430 - Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. | Biotech Hunter | Biotech Hunter